Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
6(66.7%)
Phase 3
2(22.2%)
Phase 1
1(11.1%)
9Total
Phase 2(6)
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT04738162Phase 2Completed

Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors

Role: collaborator

NCT03897491Phase 2Active Not Recruiting

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

Role: lead

NCT04469699Phase 2Terminated

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Role: collaborator

NCT05590689Phase 1Recruiting

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor

Role: collaborator

NCT03606122Phase 2Completed

5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities

Role: lead

NCT02355899Phase 2Completed

Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

Role: lead

NCT01110954Phase 2Terminated

Fluorescence-guided Resection in Breast Cancer

Role: lead

NCT01571336Completed

Photodynamic Therapy of Actinic Keratoses With Alacare®

Role: lead

NCT00308867Phase 3Completed

PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK

Role: lead

NCT00308854Phase 3Completed

Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK

Role: lead

All 10 trials loaded